Total Payments
$4,693
2024 Payments
$730.80
Companies
34
Transactions
201
Medicare Patients
21,748
Medicare Billing
$11.1M
Payment Breakdown by Category
Food & Beverage$4,658 (99.2%)
Education$35.67 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,658 | 198 | 99.2% |
| Education | $35.67 | 3 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $844.75 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $542.01 | 21 | $0 (2024) |
| Clovis Oncology, Inc. | $503.67 | 33 | $0 (2020) |
| Merck Sharp & Dohme LLC | $503.37 | 25 | $0 (2024) |
| TESARO, Inc. | $493.09 | 23 | $0 (2019) |
| Ethicon US, LLC | $308.60 | 16 | $0 (2024) |
| Eisai Inc. | $278.54 | 10 | $0 (2024) |
| Genentech USA, Inc. | $186.22 | 6 | $0 (2022) |
| DAVOL INC. | $137.28 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $121.26 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $730.80 | 24 | GlaxoSmithKline, LLC. ($161.65) |
| 2023 | $560.09 | 28 | GlaxoSmithKline, LLC. ($137.48) |
| 2022 | $711.99 | 23 | GlaxoSmithKline, LLC. ($351.32) |
| 2021 | $328.56 | 14 | GlaxoSmithKline, LLC. ($150.00) |
| 2020 | $163.83 | 11 | Ethicon US, LLC ($46.43) |
| 2019 | $749.98 | 36 | TESARO, Inc. ($232.16) |
| 2018 | $852.49 | 42 | Clovis Oncology, Inc. ($243.33) |
| 2017 | $595.66 | 23 | AstraZeneca Pharmaceuticals LP ($128.76) |
All Payment Transactions
201 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/06/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.27 | General |
| Category: NONE | ||||||
| 08/09/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Oncology | ||||||
| 07/23/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $17.75 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 06/20/2024 | Ethicon US, LLC | Echelon Circular (Device), SURGIFLO Hemostatic Matrix | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Endo-Mechanical | ||||||
| 06/14/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $121.85 | General |
| Category: Oncology | ||||||
| 03/29/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $121.26 | General |
| 02/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Oncology | ||||||
| 01/26/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: ONCOLOGY | ||||||
| 12/15/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 94 | 5,269 | 212,922 | $10.3M | $2.3M |
| 2022 | 89 | 4,737 | 220,554 | $10.5M | $2.2M |
| 2021 | 98 | 6,107 | 361,285 | $17.6M | $3.8M |
| 2020 | 94 | 5,635 | 263,985 | $12.8M | $2.8M |
Total Patients
21,748
Total Services
1,058,746
Medicare Billing
$11.1M
Procedure Codes
375
All Medicare Procedures & Services
375 procedure records from CMS Medicare Utilization — Page 1 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 46 | 20,700 | $3.9M | $893,569 | 22.9% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 5,760 | $943,200 | $218,947 | 23.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 83 | 8,520 | $599,552 | $154,555 | 25.8% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2023 | 31 | 6,590 | $731,095 | $147,177 | 20.1% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2023 | 11 | 3,090 | $487,324 | $111,897 | 23.0% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 17 | 2,350 | $409,206 | $82,513 | 20.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 21 | 2,210 | $352,340 | $79,163 | 22.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 32 | 732 | $346,295 | $62,199 | 18.0% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 37 | 3,900 | $310,050 | $61,937 | 20.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 62 | 66,750 | $257,655 | $57,747 | 22.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 272 | 553 | $249,562 | $50,166 | 20.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 50 | 16,940 | $185,154 | $40,129 | 21.7% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 54 | 93 | $152,027 | $31,073 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 217 | $124,744 | $25,665 | 20.6% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 34 | 34 | $98,269 | $23,091 | 23.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 341 | 933 | $84,772 | $18,886 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 165 | 232 | $94,963 | $18,847 | 19.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 41 | 87 | $71,545 | $14,743 | 20.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 206 | 288 | $57,145 | $12,616 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 144 | 172 | $49,528 | $9,796 | 19.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $45,051 | $9,562 | 21.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 101 | 210 | $46,003 | $9,325 | 20.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 106 | $40,888 | $8,827 | 21.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 57 | 132 | $33,279 | $6,623 | 19.9% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 12 | 8,520 | $29,224 | $6,563 | 22.5% |
About Dr. Mark Reed, MD
Dr. Mark Reed, MD is a Gynecologic Oncology healthcare provider based in Germantown, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477585347.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Reed, MD has received a total of $4,693 in payments from pharmaceutical and medical device companies, with $730.80 received in 2024. These payments were reported across 201 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($4,658).
As a Medicare-enrolled provider, Reed has provided services to 21,748 Medicare beneficiaries, totaling 1,058,746 services with total Medicare billing of $11.1M. Data is available for 4 years (2020–2023), covering 375 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Other Specialties Gynecologic Oncology, Gynecologic Oncology
- Location Germantown, TN
- Active Since 07/07/2006
- Last Updated 01/25/2022
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1477585347
Products in Payments
- ZEJULA (Drug) $1,176
- Rubraca (Drug) $489.48
- KEYTRUDA (Biological) $455.98
- LYNPARZA (Drug) $333.76
- Lenvima (Drug) $278.54
- ENSEAL Product Family (Device) $227.65
- JEMPERLI (Biological) $162.25
- Avastin (Biological) $152.47
- CFN CHLORAPREP (Device) $137.28
- TIVDAK (Biological) $130.25
- FASLODEX (Drug) $116.95
- Rezlidhia (Drug) $63.94
- LYNPARZA (Biological) $47.39
- SPY-PHI SYSTEM (Device) $45.41
- Neulasta (Biological) $43.17
- INJECTAFER (Drug) $40.09
- THERASPHERE-BIO (Device) $40.03
- Enseal X1 (Device) $32.13
- PYRUKYND (Drug) $29.72
- JEVTANA (Drug) $29.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Germantown
Mr. Todd Tillmanns, M.d, M.D
Gynecologic Oncology — Payments: $114,761
Gynecologic Oncology $114,761
Dr. Adam Elnaggar, Md, MD
Gynecologic Oncology — Payments: $47,243
Gynecologic Oncology $47,243
Dr. Michael Ulm, M.d, M.s, M.D, M.S
Gynecologic Oncology — Payments: $7,384
Gynecologic Oncology $7,384
Linda Smiley, Md, MD
Gynecologic Oncology — Payments: $6,401
Gynecologic Oncology $6,401
Dr. Laura Harbin, Md, MD
Gynecologic Oncology — Payments: $1,816
Gynecologic Oncology $1,816